Moderna ( (MRNA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Moderna’s stock took a significant hit due to the company lowering its 2025 revenue projection by $1 billion, which is a result of reduced demand for its COVID-19 vaccines and a flawed strategy for its RSV shots. The RSV vaccines received limited recommendations from the CDC, resulting in minimal sales. Moderna’s CEO, Stéphane Bancel, acknowledged an overly optimistic outlook in the RSV market amid regulatory delays. This revelation caused a near 20% drop in Moderna’s share price, adding to a broader 67% decline over the past year. Following this announcement, trading volumes surged, and analysts are now expected to reassess their ratings and price targets for the company.
More about Moderna
YTD Price Performance: 0.60%
Average Trading Volume: 8,223,292
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $16.26B
For further insights into MRNA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.